Business highlights in Q3 2025
- In May the Company announced that the board of directors of Initiator Pharma A/S had resolved on a rights issue amounting to SEK 56 million, if fully subscribed. In total 85% of the share issue was covered by presubscriptions and guarantees.
- In May the Company announced the expansion of the FSD program to target vulvodynia, and that the company had signed a financing agreement with MAC Clinical Research worth up to GBP 2.5 million for partial financing of a Phase IIa clinical trial in vulvodynia with Pudafensine .
Business highlights after this reporting period
- In July the Company announced the outcome of the rights issue. In total 45.7% of the rights issue was subscribed for with or without subscription rights, and another 40,4 percent subscribed through guarantee undertakings, in total ca 86% of the rights issue, providing the Company with proceeds of approximately SEK 48.3 million before deduction of costs related to the rights issue.
Financial Highlights
| Third Quarter (2025-04-01 – 2025-06-30) |
| Net revenue were KDKK 0 (0) |
| Operating loss, EBIT was KDKK -4,318 (-3,233) |
| Earnings per share before and after dilution was DKK -0.06 (-0.06) |
| Cash: KDKK 28,674 (11,979) |
| Solidity: 88% (92%) |
| First Nine Months (2025-01-01 – 2025-06-30) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -10,815 (-11,801) |
| Earnings per share before and after dilution was DKK –0.16 (-0.22) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/